OPR - Delayed Quote • USD JSPR Oct 2024 30.000 call (JSPR241018C00030000) Follow 5.88 0.00 (0.00%) At close: April 17 at 9:48 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for JSPR241018C00030000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: JSPR Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
